在CRSwNP中使用Dupilumab的两年转折点:控制,缓解和缩减剂量
Eugenio De Corso1, Claudio Montuori1,2, Carlotta Pipolo3
1Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
杜皮卢马布在两年内有效治疗严重的慢性鼻炎 (CRSwNP),显示症状持续改善和良好的安全性. 治疗的逐渐减少没有影响结果,即使是迟到的反应者也受益.
科学领域:
- 免疫学
- 耳鼻喉科
- 药理学
背景情况:
- 严重的,不受控制的长期鼻炎 (CRSwNP) 需要有效的长期治疗.
- 现有的对CRSwNP的真实数据仅限于较短的持续时间和较小的队列.
研究的目的:
- 评估dupilumab在严重,不受控制的CRSwNP患者中的2年有效性和安全性.
- 在实际临床实践中评估治疗反应,疾病控制和缓解率.
主要方法:
- 这是一项涉及926名患有严重,不受控制的CRSwNP的多中心研究.
- 在24个月内对dupilumab对鼻积分 (NPS),鼻阻塞 (VAS),SNOT-22和嗅觉的影响的评估.
- 对治疗反应,疾病控制,缓解和不良事件的分析.
主要成果:
- 在24个月后,观察到NPS,鼻腔阻塞,SNOT-22和嗅觉的显著改善 (p < 0. 0001).
- 根据EPOS/ Euforea标准,91. 2%的患者获得良好至优异的反应.
- 在18. 7%的患者中,dupilumab逐渐降至q4w,但没有影响结果;不良反应大多为轻度至中度.
结论:
- 在大量现实人群中,dupilumab在两年内证明了严重的CRSwNP的持续有效性和安全性.
- 治疗持续支持有意义的临床益处,包括对晚期反应患者.
- 需要标准化标准来评估长期疾病控制和缓解.
更多相关视频
06:13Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation
Published on: June 20, 2018
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Therapy
Antianxiety Medications
